Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Year range
1.
Acta Pharmaceutica Sinica B ; (6): 2990-3005, 2022.
Article in English | WPRIM | ID: wpr-939957

ABSTRACT

The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies. At present, a variety of small molecule PROTACs have entered the clinical trial. However, as small molecule PROTACs flourish, non-small molecule PROTACs (NSM-PROTACs) such as peptide PROTACs, nucleic acid PROTACs and antibody PROTACs have also advanced considerably over recent years, exhibiting the unique characters beyond the small molecule PROTACs. Here, we briefly introduce the types of NSM-PROTACs, describe the advantages of NSM-PROTACs, and summarize the development of NSM-PROTACs so far in detail. We hope this article could not only provide useful insights into NSM-PROTACs, but also expand the research interest of NSM-PROTACs.

2.
Journal of Pharmaceutical Practice ; (6): 44-47, 2022.
Article in Chinese | WPRIM | ID: wpr-907153

ABSTRACT

Objective To evaluate the in vitro synergistic antifungal activity of HDAC inhibitors in combination with azole drugs against azoles-resistant Candida strains. Methods The checkerboard microdilution method was used to evaluate the antifungal activity of the HDAC inhibitors in combination with azole drugs against clinically drug-resistant strains. The fungistatic activity and toxicity of Rocilinostat was determined through time-growth curve assay and cytotoxicity assay. Results The compound Rocilinostat combined with azole drugs showed excellent synergistic antifungal activity against a variety of azoles-resistant Candida albicans and Candida glabrata. The combination of high concentration Rocilinostat with FLC exhibited fungistatic effects. Very low toxicity was detected with Rocilinostat towards normal cells. Rocilinostat showed better HDAC inhibitory activity than SAHA. Conclusion As a fungi HDAC inhibitor, Rocilinostat has excellent in vitro synergistic antifungal activity and no severe toxicity to normal human cells.

3.
International Journal of Cerebrovascular Diseases ; (12): 948-951, 2012.
Article in Chinese | WPRIM | ID: wpr-430578

ABSTRACT

Resistin is a recently discovered polypeptide hormone.Studies have shown that resistin is closely associated with atherosclerosis by promoting inflammatory response and adhesion of vascular endothelial cells,transformation from macrophages to foam cells,vascular smooth muscle cell proliferation and migration,increasing plaque instability,as well as promoting carbohydrate and lipid metabolism disorders,etc.Resistin can promote the occurrence and development of ischemic cerebrovascular disease.It may become a potential biological marker and intervention target.

SELECTION OF CITATIONS
SEARCH DETAIL